Much-Hyped Alzheimer's Drug Fails, Sending Biogen Shares Down Nearly 30 Percent

Biogen shares fell nearly 30 percent this morning after the news that the company is discontinuing trials on aducanumab, a drug that was supposed to help treat Alzheimer's. Biogen's failure was disappointing but not unique — 99 percent of Alzheimer's trials fail. Here & Now's Jeremy Hobson talks to Roben Farzad (@robenfarzad), host of NPR One's "Full Disclosure."